Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females

Table 2 QALY weights applied

QALY weights the general population ¹
	Men	Women		QALY
Age group	QALY	QALY	Occurrence/illness	Utility score²	Duration
15-19	0.9373	0.9203
20-24	0.9373	0.9203	CIN1	0.93	2 months
25-29	0.9373	0.9203
30-34	0.9355	0.9118	CIN2-3	0.87	2 months
35-39	0.9197	0.8898
40-44	0.9118	0.8763	Genital warts	0.91	85 days
45-49	0.9050	0.8751
50-54	0.8813	0.8499	Cervical cancer, fatal	0.76-0, 67
55-59	0.8870	0.8542	Cervical cancer, survivors	0.76	5 years
60-64	0.8747	0.8552
65-69	0.8801	0.8098	Genital cancer, fatal	0.76-0.67
70-74	0.8437	0.8320	Genital cancer, survivors	0.76	5 years
75-79	0.8429	0.7837
80-84	0.7855	0.6919	Head & neck cancer, fatal	0.76-0.67
85-	0.7855	0.6919	Head & neck cancer, survivors	0.76	5 years

¹Unpublished data from survey performed by National Institute of Public Health, University of Southern Denmark (personal communication). These data, pooled with two other Danish surveys, are published on a more aggregate level in Sørensen et al., 2009 [31].
²Source: [18].

ISSN: 1478-7547